A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
| العنوان: | A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L |
|---|---|
| المؤلفون: | Yukito Ichinose, Takeharu Yamanaka, Hideyuki Harada, Kazuhiko Nakagawa, Junichi Shimizu, Masaaki Kataoka, Yoichi Nakanishi, Nobuyuki Yamamoto, Makoto Nishio, Takeshi Kodaira, Toshiaki Takahashi, Naonobu Kunitake, Takuyo Kozuka, Shinichi Tsutsumi, Naruo Yoshimura, Takashi Seto, Yasumasa Nishimura, Tomonari Sasaki, Hiromoto Kitajima |
| المصدر: | British Journal of Cancer |
| بيانات النشر: | Nature Publishing Group UK, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Vinorelbine, Article, 03 medical and health sciences, 0302 clinical medicine, Japan, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Neoplasm Staging, Tegafur, Chemotherapy, Radiotherapy, business.industry, Standard treatment, Hazard ratio, Dose fractionation, Chemoradiotherapy, medicine.disease, Survival Analysis, Radiation therapy, Drug Combinations, Oxonic Acid, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Dose Fractionation, Radiation, Cisplatin, business, Non-small-cell lung cancer, medicine.drug |
| الوصف: | Background Cisplatin-based chemoradiotherapy is the standard treatment for unresectable, locally advanced non-small-cell lung cancer (NSCLC). This trial evaluated two experimental regimens that combine chemotherapy with concurrent radiotherapy. Methods Eligible patients with unresectable stage III NSCLC were randomised to either the SP arm (S-1 and cisplatin) or VP arm (vinorelbine and cisplatin), with early concurrent thoracic radiotherapy of 60 Gy, comprising 2 Gy per daily fraction. The primary endpoint was the overall survival rate at 2 years (2-year overall survival (OS)) (Study ID: UMIN000002420). Results From September 2009 to September 2012, 112 patients were enroled. Of the 108 eligible patients, the 2-year OS was 75.6% (80% confidence interval (CI), 67–82%) in the SP arm and 68.5% (80% CI: 60–76%) in the VP arm. The hazard ratio (HR) for death between the two arms was 0.85 (0.48–1.49). The median progression-free survival was 14.8 months for the SP arm and 12.3 months for the VP arm with an HR of 0.92 (0.58–1.44). There were four treatment-related deaths in the SP arm and five in the VP arm. Conclusions The null hypotheses for 2-year OS were rejected in both arms. The West Japan Oncology Group will employ the SP arm as the investigational arm in a future phase III study. |
| اللغة: | English |
| تدمد: | 1532-1827 0007-0920 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e28fbeadb176d27cd8526b4549cc2749 http://europepmc.org/articles/PMC6173687 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e28fbeadb176d27cd8526b4549cc2749 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15321827 00070920 |
|---|